Last reviewed · How we verify
Luspatercept Injection [Reblozyl]
Luspatercept is a recombinant fusion protein that acts as a ligand trap for members of the TGF-β superfamily, modulating Smad2/3 signaling to enhance erythroid maturation.
Luspatercept is a recombinant fusion protein that acts as a ligand trap for members of the TGF-β superfamily, modulating Smad2/3 signaling to enhance erythroid maturation. Used for Myelodysplastic syndromes (MDS) with ring sideroblasts, Beta-thalassemia.
At a glance
| Generic name | Luspatercept Injection [Reblozyl] |
|---|---|
| Also known as | ACE-536 |
| Sponsor | Groupe Francophone des Myelodysplasies |
| Drug class | Erythroid maturation agent |
| Target | TGF-β superfamily ligands (GDF11, activin A) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By binding to growth differentiation factor 11 (GDF11) and activin A, luspatercept prevents their interaction with the activin type II receptor, thereby reducing inhibitory signals in the bone marrow and promoting the maturation of red blood cells.
Approved indications
- Myelodysplastic syndromes (MDS) with ring sideroblasts
- Beta-thalassemia
Common side effects
- Fatigue
- Headache
- Arthralgia
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: